D. Boral Capital Reiterates Buy Rating for Beyond Air (NASDAQ:XAIR)

Beyond Air (NASDAQ:XAIR)‘s stock had its “buy” rating reissued by equities research analysts at D. Boral Capital in a report released on Wednesday,Benzinga reports. They currently have a $11.00 price target on the stock. D. Boral Capital’s price objective indicates a potential upside of 464.10% from the company’s current price.

Several other equities research analysts have also issued reports on the stock. Rodman & Renshaw initiated coverage on shares of Beyond Air in a research note on Tuesday. They set a “buy” rating on the stock. Weiss Ratings reaffirmed a “sell (e)” rating on shares of Beyond Air in a research note on Monday, December 22nd. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $11.00.

Beyond Air Stock Performance

Shares of XAIR stock opened at $1.95 on Wednesday. Beyond Air has a 1 year low of $0.67 and a 1 year high of $10.40. The firm has a market capitalization of $15.62 million, a price-to-earnings ratio of -0.26 and a beta of 0.34. The company has a debt-to-equity ratio of 0.77, a current ratio of 4.24 and a quick ratio of 3.73. The business has a fifty day moving average of $1.15 and a 200 day moving average of $2.07.

Beyond Air (NASDAQ:XAIR) last issued its earnings results on Monday, November 10th. The company reported ($1.25) EPS for the quarter, missing analysts’ consensus estimates of ($1.10) by ($0.15). The firm had revenue of $1.82 million during the quarter, compared to analysts’ expectations of $2.54 million. Beyond Air had a negative net margin of 632.51% and a negative return on equity of 261.08%. As a group, research analysts expect that Beyond Air will post -0.79 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Alpine Global Management LLC purchased a new stake in Beyond Air in the 3rd quarter valued at $25,000. Geode Capital Management LLC lifted its stake in shares of Beyond Air by 1.5% in the second quarter. Geode Capital Management LLC now owns 838,319 shares of the company’s stock valued at $144,000 after purchasing an additional 12,598 shares during the period. Virtu Financial LLC purchased a new position in Beyond Air in the 3rd quarter valued at approximately $48,000. Osaic Holdings Inc. raised its stake in shares of Beyond Air by 26.4% during the 2nd quarter. Osaic Holdings Inc. now owns 162,560 shares of the company’s stock worth $29,000 after buying an additional 34,000 shares during the last quarter. Finally, Wealth Effects LLC increased its stake in shares of Beyond Air by 42.5% during the 2nd quarter. Wealth Effects LLC now owns 278,100 shares of the company’s stock worth $48,000 after purchasing an additional 83,000 shares in the last quarter. Hedge funds and other institutional investors own 31.50% of the company’s stock.

About Beyond Air

Beyond Air, Inc is a clinical-stage medical technology company focused on the development and commercialization of inhaled nitric oxide (NO) therapy for pulmonary and respiratory diseases. The company’s proprietary LungFit® platform delivers pulsed, low-dose nitric oxide gas through compact, portable devices designed to support treatments in both inpatient and outpatient settings. Beyond Air’s approach leverages NO’s antimicrobial, vasodilatory and anti-inflammatory properties to address a range of unmet needs in respiratory medicine.

The company’s lead candidate, LungFit® PH, is under investigation for the treatment of pulmonary hypertension, with ongoing clinical studies assessing its impact on pulmonary arterial pressure and exercise capacity.